Skip to main content
Premium Trial:

Request an Annual Quote

Fleury Group to License IDbyDNA NGS Platform

The story has been amended to update the number of bacterial, fungal, and viral respiratory pathogens detected by IDbyDNA's technology.

NEW YORK (GenomeWeb) – IDbyDNA announced today that it has signed a licensing agreement with Brazil-based Fleury Group to offer IDbyDNA's Explify platform for clinical metagenomic testing in South America.  

As part of the collaboration, Fleury will integrate Explify into its own laboratory workflow and develop a full suite of Explify-based clinical testing, starting with Explify Respiratory. The next-generation sequencing-based tool detects more than 3,000 common and rare bacterial, fungal, and viral respiratory pathogens.

"Working with IDbyDNA allows us to enhance our pathogen detection portfolio, adding novel genomic diagnostic tests for complex infection cases [and] assisting physicians to get a fast and safe solution," Fleury Group Chief Medical Officer Edgar Gil Rizzatti said in a statement.

In addition, Fleury plans to quickly develop and launch other NGS-based metagenomic tests using the Explify platform such as for the analyses of brain, joint, and blood-based infections.

"These collaborations will allow us to rapidly form distribution channels through our top tier partner laboratories, such as Fleury Group, with fast and agile product development for their various markets, and robust scalability according to our partners' size and needs," IDbyDNA CEO Guochun Liao said in a statement. "Using this mechanism … we're also getting access to more pathogen genomic information to improve our database even further."

Earlier this year, IDbyDNA partnered with Locus Biosciences to create a companion diagnostic tool using the firm's Explify platform.